During the course of its development, HIFU has been applied to a multitude of clinical problems. Its earliest application was in neurosurgery to treat patients with neurological disorders such as Parkinson’s disease. Other applications of interest include therapy for stopping hemorrhage from organs during surgery or due to physical trauma as well as ultrasound aided drug delivery to the brain. The idea here is to use HIFU to temporarily disrupt the blood-brain barrier, allowing drugs to flow into the brain. Most of the applications of HIFU that are currently being investigated are in cancer treatment of various types of tumors. These include tumors of the liver, prostate, bladder, kidney, pancreas, breast, pancreas, bone, breast, and brain as well as uterine fibroid tumors. HIFU can be used both as a primary and salvage treatment after radiation in cancer therapies.
Additionally, catheter-based HIFU probes are also under investigation for cardiac ablation therapies for heart arrhythmias, similar in fashion to radio frequency and cryogenic ablation probes. Current innovations in clinical instrumentation, as outlined in the instrumentation section of this website, are focused on transrectal treatment of prostate cancer. HIFU treatment, while permitted in treatment of prostate cancer around the world, is in phase III clinical trials (Sonablate) in the United States. Initial data shows that while HIFU is effective in treatment of prostate cancer, it is still prone to the same complications as other ablation procedures, including incontinence and impotence. |
|
Schematic showing transrectal treatment of prostate cancer usingJune 11, 2008
|
|
Sonablate probe, courtesy of Focus Surgery |
|